Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the NSCLC landscape after KEYNOTE-189 data, specifically PD-1 combo programs

Ticker(s): MRK, ARMO, NKTR

Who's the expert?

Name: Dr Jack West - MD

Institution: Swedish Cancer Institute

  • Medical oncologist (specialty in lung cancer) and Medical Director of the Thoracic Oncology Program at the Swedish Cancer Institute.
  • Leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee as a Study Coordinator/Principal Investigator.
  • Has published numerous articles in peer-reviewed literature, authored several book chapters, and serves as the Web Editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease.

Interview Questions
Q1.

Please describe your background treating NSCLC.

Added By: joe_mccann
Q2.

What are your thoughts on KEYNOTE-189

Added By: joe_mccann
Q3.

More questions to come.

Added By: joe_mccann

Are You Interested In These Questions?

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.